1,060 results on '"Vermorken, Jan B"'
Search Results
2. Treatment Intensification in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: What Are the Options and for Whom?
3. Cetuximab : its unique place in head and neck cancer treatment
4. Season of radiotherapy and outcomes of head & neck cancer patients in the MACH-NC & MARCH meta-analyses
5. Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in Older Patients: Are New Agents Bringing New Hope?
6. Critical Issues in Head and Neck Oncology
7. Steering decision making by terminology: oligometastatic versus argometastatic
8. Gynecologic Cancer
9. Where and when to Use Induction Chemotherapy in Head and Neck Squamous Cell Cancer
10. High-Dose Three-Weekly or Low-Dose Weekly Cisplatin during Radiation, What to Prefer?
11. ESO-ESSO-ESTRO Multidisciplinary Course in Oncology for Medical Students: 4 Years of Experience (2016–2019)
12. The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry
13. Prognostic factor analysis and long-term results of the TAX 323 (EORTC 24971) study in unresectable head and neck cancer patients
14. Current management of stage IV nasopharyngeal carcinoma without distant metastasis
15. Treatment of Elderly Patients with Head and Neck Cancer
16. Critical Issues in Head and Neck Oncology
17. Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher
18. Management of locally recurrent nasopharyngeal carcinoma
19. Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: A review of the literature
20. Treatment in the Elderly
21. Immunotherapeutic Approaches
22. Patient and Treatment Factors in Concurrent Chemoradiotherapy
23. Multidisciplinary Decision Making and Head and Neck Tumor Boards
24. The 'Make Sense Campaign': An Initiative of the European Head and Neck Society
25. Academia Oncology: a forum for interdisciplinary cancer research
26. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial
27. Altered fractionation radiotherapy combined with concurrent low-dose or high-dose cisplatin in head and neck cancer: A systematic review of literature and meta-analysis
28. Unraveling the Mechanism of Radiosensitization by Gemcitabine: The Role of TP53
29. Human Papillomavirus (HPV): A Criterion for Therapeutic Decision in Squamous Cell Carcinoma of the Head and Neck?
30. Cell Based Therapy: Modified Cancer Cells
31. Season of radiotherapy and outcomes of head & neck cancer patients in the MACH-NC & MARCH meta-analyses
32. Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data
33. Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy
34. HIPEC in advanced epithelial ovarian cancer: why is there controversy?
35. Systemic Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
36. Editorial: Head and neck cancer in the elderly
37. Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review
38. Systemic treatment in elderly head and neck cancer patients: recommendations for clinical practice
39. Supplementary Table 2 from Clinical Effects of Adjuvant Active Specific Immunotherapy Differ between Patients with Microsatellite-Stable and Microsatellite-Instable Colon Cancer
40. Supplementary Figure 2 from Clinical Effects of Adjuvant Active Specific Immunotherapy Differ between Patients with Microsatellite-Stable and Microsatellite-Instable Colon Cancer
41. Supplementary Table 1 from Clinical Effects of Adjuvant Active Specific Immunotherapy Differ between Patients with Microsatellite-Stable and Microsatellite-Instable Colon Cancer
42. Supplementary Figure 1 from Clinical Effects of Adjuvant Active Specific Immunotherapy Differ between Patients with Microsatellite-Stable and Microsatellite-Instable Colon Cancer
43. Supplementary Figure 3 from Clinical Effects of Adjuvant Active Specific Immunotherapy Differ between Patients with Microsatellite-Stable and Microsatellite-Instable Colon Cancer
44. Supplementary Figure 4 from Clinical Effects of Adjuvant Active Specific Immunotherapy Differ between Patients with Microsatellite-Stable and Microsatellite-Instable Colon Cancer
45. Editorial: Insights in head and neck cancer: 2021
46. Novel Immunotherapeutic Approaches to Treating HPV-Related Head and Neck Cancer
47. The role of systemic therapy in the management of sinonasal cancer: A critical review
48. Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensus
49. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
50. Barriers to clinical trial recruitment in head and neck cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.